Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04889937
Other study ID # MDACC Protocol ID: 2021-0061
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 7, 2021
Est. completion date July 2023

Study information

Verified date March 2023
Source Leuko Labs, Inc.
Contact Alvaro Sánchez-Ferro, MD, PhD
Phone +1 617 419 0974
Email alvaro@leuko.io
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Single-site non-significant risk, open-label clinical investigation designed to validate the usability, adherence, and preliminary diagnostic performance of a novel technology to detect neutropenia. Study participants will be managed as per the standard of care practice with a baseline and nadir visit including laboratory determinations. Participants will also be evaluated with the device at both time points and with daily measurements during the two-week period in between.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date July 2023
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 7 Years to 39 Years
Eligibility Inclusion Criteria 1. Study subjects, or their parent/legal guardian for subjects <18 years, must be able to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations. Subjects between the ages of 7 and 17.9 years must provide assent. 2. Male or Female aged 7 years to 65 years. 3. Adults (> 18 years) diagnosed Diagnosed with Hodgkin/Non-Hodgkin Lymphoma or breast cancer. 4. Children and adolescents (7 - 18 years) with liquid or solid tumors. 5. Scheduled treatment with cytotoxic chemotherapy with an associated high/intermediate risk of neutropenia (table 1) 30. 6. Able (in the investigator's opinion) and willing to comply with all study requirements. Exclusion Criteria 1. Participants with amputations, congenital malformations, or any severe abnormalities of the hands as determined by the investigator. 2. Participants with a history of vasculitis, Raynaud syndrome, scleroderma, mixed connective tissue disease, or any other rheumatologic systemic condition that could produce microcirculatory changes in the nailfold. 3. Participants with circulating tumor cells in previous or current lab determinations. 4. Adult (>18 years) participants with leukemia of all types and pediatric (7-18 years) participants with leukemia that are either not in remission or in the minimal residual disease category. 5. Participants with any condition producing significant tremor (e.g., essential tremor, Parkinson´s disease, dystonic tremor). 6. Unstable participants (pediatric or adults) or adult participants with hypotension (systolic blood pressure <90 and diastolic blood pressure < 60mmHg). 7. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. 8. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrolment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PointCheck
PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose

Locations

Country Name City State
United States MD Anderson Cancer Center Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
Leuko Labs, Inc. Center for Advancing Point of Care Technologies in Heart, Lung, Blood and Sleep Disorders, M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Predictive capacity of PointCheck An exploratory analysis about the number of days before the second lab determination that PointCheckTM detected severe neutropenia will be investigated in those participants with severe neutropenia at the nadir visit. Also, exploratory analysis will be conducted in patients developing febrile neutropenia (axillary temperature =100.4°F and grade III/IV neutropenia documented in the lab report) during the study to evaluate how many days before the appearance of fever the device detected severe neutropenia during the at home phase of the study. Up to three-weeks
Other Diagnostic performance for a second cutoff The preliminary diagnostic accuracy to detect grade III neutropenia according to CTCAE V5 (<1000 ANC/mm3) 13 measured by the sensitivity and the specificity will be the evaluated with reference to the corresponding laboratory measures acquired at the nadir (follow up) visit. Up to three-weeks
Other Clinical Utility Assessment Survey completed by the clinical team at the baseline visit assessing the clinical utility of PointCheckTM Up to three-weeks
Primary Usability of PointCheck The study will confirm if participants can acquire good quality videos in a home like setting.
The System Usability Scale (0-100 higher scored indicate a better usability) will be completed by the participants after completing the follow up visit.
Up to three-weeks
Secondary Accuracy of PointCheck The preliminary diagnostic accuracy to detect grade IV neutropenia according to CTCAE V5 (<500 ANC/mm3) measured by the sensitivity and the specificity will be the evaluated with reference to the corresponding laboratory measures acquired at the nadir (follow up) visit. Up to three-weeks
Secondary Repeatability of PointCheck The % agreement of the device to classify neutropenia compared to the laboratory reference will be established Up to three-weeks
Secondary Number of participants with device-related adverse events as assessed by CTCAE v5.0 The number (and %) of AEs, SAEs and their relationship with the device use will be the safety endpoint Up to three-weeks
Secondary Adherence to PointCheck The number of days that the participant used the device will be used to evaluate adherence. Up to three-weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Not yet recruiting NCT05820126 - Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial Phase 2
Active, not recruiting NCT04509765 - A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT N/A
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Withdrawn NCT03986086 - MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT02512666 - Non Invasive Optical Imaging of WBC Count N/A
Not yet recruiting NCT02193399 - Physiotherapy in Hematopoietic Stem Cell Transplantation N/A
Withdrawn NCT02207764 - Reiki as a Complementary Therapy: A Pilot Study N/A
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Terminated NCT01215981 - Influenza Vaccine Post Allogeneic Transplant N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Withdrawn NCT04392128 - Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) Phase 2
Recruiting NCT06102213 - Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation Phase 2
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Completed NCT03654404 - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients N/A
Recruiting NCT05384288 - Response to Influenza Vaccination in Pediatric Oncology Patients
Recruiting NCT05084027 - Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT Phase 2
Active, not recruiting NCT05180838 - Remote Temperature Data for Early Detection of Febrile Neutropenia

External Links